Figure S6 from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib
Year: 2023
Type: other
Abstract: Osimertinib combined with a BET inhibitor or degrader shows enhanced effects on decreasing the survival of HCC827/AR cells.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361879181